Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprise the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
May 8, 2001
Assignee:
The Children's Medical Center
Inventors:
Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a material is disclosed. The particular material used is a 1H-1,2,4-triazole derivative. These compounds can also be used to treat viral infections.
Abstract: A composition and method of preventing or inhibiting tumor growth, and of treating malignant melanoma, without toxic side effects are disclosed. Betulinic acid or a betulinic acid derivative is the active compound of the composition, which is topically applied to the situs of tumor.
Type:
Grant
Filed:
November 10, 1998
Date of Patent:
May 1, 2001
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
John M. Pezzuto, Tapas K. DasGupta, Darrick S. H. L. Kim
Abstract: Antibiotic 10381a1, wherein R is hydrogen, is a cytosine-containing antibiotic producible by culturing the novel microorganism Streptomyces arginensis in an aqueous medium and isolation thereof. Derivatives wherein R is a C1 to C3 alkyl ester of antibiotic 10381a1, are also disclosed along with the pharmaceutically acceptable salts of both the native and esterified forms. Antibiotic 10381a1 inhibits the growth of selected species of yeast, fungi and bacteria. This invention also relates to a novel process for the preparation of the antibiotics 10381b and to a method of using antibiotics 10381b to promote growth in meat-producing animals. These antibiotics are also obtained by the fermentation of a nutrient medium with the novel microorganism Streptomyces arginensis and are active against selected species of bacteria.
Type:
Grant
Filed:
August 10, 1999
Date of Patent:
May 1, 2001
Assignee:
Pharmacia & Upjohn Company
Inventors:
Alexander D. Argoudelis, Franklin B. Shilliday, Alice L. Laborde, Scott E. Truesdell, Oldrich K. Sebek
Abstract: A method and composition for treating a bacterial infection in humans and animals is disclosed. The composition contains an anti-bacterial agent that inhibits or kills a variety of Gram-negative and Gram-positive pathogenic bacteria, including several previously shown to be drug-resistant. In particular, the anti-bacterial agent comprises an antibiotic produced by members of the Alcaligenes genus. For instance, in one embodiment, the antibiotic is produced by the M3A strain of Alcaligenes faecalis. The antibiotic of the present invention can be administered parenterally or via a mucosal route.
Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Abstract: The present invention is based on the method of treating a patient suffering from leukemia comprising administering a therapeutically effective amount of the compound 2-([(3-hydroxypropyl)amino]-6-benzylamino)-9-isopropylpurine or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
March 4, 1998
Date of Patent:
April 24, 2001
Assignee:
Institute of Experimental Botany of the Academy of Sciences
of the Czech Republic
Inventors:
Libor Havlicek, Miroslav Strnad, Marian Hajduch
Abstract: The invention relates to methods for preventing, inhibiting, or suppressing tumors by administering to a person in need of such treatment a therapeutically effective amount of one or more flavanolignanes, such as silymarin, silybin, silidianin, silicristin, dehydrosilybin, mixtures thereof, or extracts thereof as an antiproliferative. The invention further relates to the antitumor pharmaceutical composition includes a therapeutically effective amount of the flavanolignane selected from the group of silymarin, silybin, silidianin, silicristin, dehydrosilybin, and mixtures thereof, in combination with a different antitumor agent. In another embodiment, the pharmaceutical composition includes a therapeutically effective amount of a flavanolignane selected from the group of silidianin, silicristin, and mixtures thereof, with a pharmaceutically acceptable carrier or excipient.
Abstract: Nigella sativa derivatives, thymoquinone (TM) and dithymoquinone (DIM) are used in treatment of parental and multi-drug resistant human cancers.
Type:
Grant
Filed:
May 28, 1999
Date of Patent:
April 17, 2001
Assignee:
University of Kentucky Research Foundation
Inventors:
Peter A. Crooks, David R. Worthen, Omar A. Ghosheh
Abstract: Pharmaceutical compositions comprising a topoisomerase I inhibitor, such as camptothecin or a camptothecin analog, and a staurosporine such as 7-hydroxystaurosporine, together with a pharmaceutically acceptable carrier or diluent are provided. In other aspects, methods of inhibiting the growth of cancer cells are provided by contacting the cells with an cell growth inhibiting amount of a topoisomerase I inhibitor, such as camptothecin or a camptothecin analog, and a staurosporine, such as 7-hydroxystaurosporine, while protecting normal cells from topoisomerase I inhibitor induced cytotoxicity.
Type:
Grant
Filed:
March 4, 1999
Date of Patent:
April 10, 2001
Assignee:
Washington State University Research Foundation
Abstract: Use of the proprietary drug amiloride for the treatment of cancer types that depend on an enzymatic cascade triggered by the activation of plasminogen to plasmin by the specific activating enzyme Urokinase Plasminogen Activator (uPA). Administration of amiloride inhibits the action of uPA, inhibits the ability of the cancer cell to attract new blood supply, blocks the Na+/H+ transporter, and inhibits ornithine decarboxylase necessary for DNA synthesis. Further, in combination with amiloride, a different step in the enzymatic cascade is targeted by a secondary agent, Batimistat, for example, which is a metalloprotease inhibitor. Additionally, the use of hydrochlorothiazide promotes excretion of potassium.
Type:
Grant
Filed:
August 6, 1999
Date of Patent:
April 10, 2001
Inventors:
Douglas McCullough Evans, Kimberly Denise Sloan-Stakleff
Abstract: Disclosed is a pharmacological composition for treating cancer cells, comprising solamargine and a pharmacologically compatible carrier or diluent.
Type:
Grant
Filed:
November 8, 1999
Date of Patent:
April 10, 2001
Assignee:
Committee on Chinese Medicine and Pharmacy Department of
Health Executive Yuan
Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to substituted 2-aryl-benzimidazoles.
Type:
Grant
Filed:
November 24, 1998
Date of Patent:
April 3, 2001
Assignee:
Cell Pathways, Inc.
Inventors:
Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
Abstract: Methods for treating or preventing breast cancer or leukemia in subjects in need of such treatment are provided which involve the administration of 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN), a retinoid which induces G0/G1 arrest and apoptosis. These methods are useful for treatment of breast cancers which express or do not express estrogen receptors.
Type:
Grant
Filed:
June 29, 1998
Date of Patent:
April 3, 2001
Assignee:
Centre International de Recherches Dermatologiques
Galderma
Abstract: A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to amino or pyridylamino cyclobutane derivatives.
Abstract: Derivatives of 4-phenylphthalazine are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.
Abstract: Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal with a stimulating amount of the interferon which exceeds parenterally administered amounts of interferon, methods of treatment with such compositions and uses of interferon in the preparation of such oromucosal compositions.
Abstract: Numerous studies have documented that medications which increase brain serotonin (5-HT) are effective anorectic agents which help obese patients lose weight and which also decrease craving for sweets and carbohydrates. Evidence from other studies also indicate that increases in brain 5-HT may help decrease craving for alcohol and cocaine. 5-hydroxy-L-tryptophan, abbreviated 5-HTP, is the immediate precursor of serotonin (5-HT). When administered in combination with an inhibitor of peripheral decarboxylase such as carbidopa, 5-HTP increases brain serotonin. Increases in synaptic 5-HT decreases the firing rate of 5-HT neurons via stimulation of inhibitory 5-HT1a receptors located on the cell bodies in the raphe. This serves as a negative feedback loop. The clinically available beta adreneric receptor antagonist medication pindolol is also a 5-HT1a antagonist, and can be used to increase the ability of 5-HTP to increase brain 5-HT. Previous studies with 5-HTP used doses exceeding 50 mg per day.
Abstract: A pharmaceutical, cosmetic and/or food composition includes a pyrazine derivative of formula (I) or (II), and/or a precursor thereof of formula (III). The composition is used for treatment of pathologies associated with prooxidant agents.
Type:
Grant
Filed:
February 17, 1998
Date of Patent:
March 20, 2001
Assignee:
Universite Catholique De Louvain Halles Universitaires
Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a 1H-1,2,4-triazole derivative along with a safe and effective amount of a chemotherapeutic agent. Potentiators can be used to enhance the effectiveness of the drugs. The triazoles and potentiators compounds can also be used to treat viral infections.